PN was orally administrated to HLP model rats, which can activate AMPK, and downregulate the liver fat synthesis pathway, with the appearance of the rising level of APN in the serum, resulting in lipid metabolism acceleration and then having an effect on NAFLD treatment (Ma, Z. et al., 2017). Here, ANPEP is linked to metabolic dysfunction-associated steatotic liver disease.